Close Menu

NEW YORK (360Dx) – Diagnostic startup InterVenn BioSciences is working to develop mass spectrometry-based glycoproteomic tests for a variety of cancers and other conditions.

The Redwood City, California-based company's lead product is an ovarian cancer assay intended to help doctors triage pelvic masses, similar to protein tests offered by firms including Vermillion and Fujirebio.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.